Get started

JAGX

JAXG, a lowkey health stock with multi bagger growth prospect!After skimming on low cap stocks which have huge growth potential but have been on signficant correction, I came across JAGX, a pharmaceutical company focused on developing plant-based, non-opioid, and sustainably derived prescription medicines. Weekly data is showing weakening of sellers. An accumulation / net buying at the current price range has been spotted. Volume have increased from 1.73M to 2.22M. Again, its a low cap -- and the catch with low cap stocks is liquidity. Be mindful on that aspect. Spotted at 0.6090 TAYOR.
NASDAQ:JAGXLong
by JSAL
JAGX BUY/LONG NOW READY! 1.90 to 29.50 by End 2022!TICKER CODE: JAGX Company Name: JAGUAR HEALTH, INC US Stocks Health Technology Pharmaceuticals: Generic Position Proposed: BUY BUY ENTRY: NOW READY (1.90-2.40) 1st Partial Take Profit: 5.45 (in 2 Months 2021) 2nd Partial Take Profit: 8.25 (Aug-Sept 2021) 3rd Partial Take Profit: 12.70 (End 2021) Expected Take Profit: 17.15 (Early - Mid 2022) Potential Take Profit: 29.50 (End 2022) NOTE THAT THE TIMELINE IS ONLY AN ESTIMATION Stop Loss: 1.40 Technical Analysis 1. LARGE INVERTED HEAD & SHOULDERS PATTERN (PARTIALLY COMPLETE) 2. Small Falling Wedge Completed 3. Fibonacci Retracement at 0.786 4. 1st Partial Take Profit is at Fibonacci Extension Level 1 Grey Zone (Safe Zone) which is also at the price range of the pole. 5. 2nd Partial Take Profit will complete the head formation of a smaller INVERTED HEAD & SHOULDERS it will also hit key horizontal structure levels which will very likely create a short consolidation
NASDAQ:JAGXLong
by traderprosignals
2
$JAGX Weekly overviewThe weekly chart looks like a textbook Primary W1 to W2 setup, with a hollow green candle last week from the previous weeks low. The primary wave 3 target here is $8.29, with a final Wave 5 target of $10.46. The weekly RSI is curving up, hoever the momentum has been falling and the stoch RSI is still trending downward, so we could see a slight dip if the overall market is red early this week. This seems likely as a lot of other stocks are showing a similar W1-W2 setup, so a corrective wave could be looming. If we look at the ichimoku cloud however, it has started opening up, so that provides a bit more conviction that, on the longer time frame, we could be heading up. Further more, by overlaying the pitckfork on our EW setup, we can get some estimates for price and time targets. If this setup follows through as expected, i will be looking to buy a pull back around $1.81-1.77 (will likely set my bid at $1.85). We should see around $5.50 by early april, and if this comes to pass it will give us further conviction. I'll be looking for my first sell taget at $8.29, around late april, followed by a consolidation to around $5 by mid may and then a final sell target between $9.80 to $10.40 sometime between late june to late july. TL:DR Buy on pullback at $1.85 this week (March 15-19) PT1 = $8.25 by late april PT2 = $9.80 by late june to late july.
NASDAQ:JAGXLong
by ir-rizzle
20
NNVC -- You Knew That Was Going to Spike AgainThat shaded box, starting from January.19th, was most likely somebody accumulating.. But it looks like the usual suspects, that being: Sabby Management Altrium Capital Empery Asset Management CVI Investments all somehow managed to miss out on this one at the exact same time, because according to the their end of year 13-G reports, they all reported 0% ownership in the company... At times, it seems like the line between hedge fund and underwriter has become blurred with these companies, where it almost looks like they are cooperating with the underwriter during the equity offering process -- but who knows.. Something about this was mentioned in an sec litigation a few years back. “The SEC alleges that a former day trader living in California, Steven Fishoff, schemed with two friends and his brother-in-law to pose as legitimate portfolio managers and induce investment bankers to bring them “over the wall” and share confidential information about an upcoming secondary offering. After promising they wouldn’t disclose the nonpublic information to others or trade an issuer’s stock before an offering was announced, they violated the agreements and tipped each other about the upcoming offerings expected to inherently depress the price of the issuer’s stock. The tippees then shorted the stock before an offering was publicly announced and assured themselves profits on the short sales after the stock price dropped”.
AMEX:NNVC
by stocktradez6
1
JAGX Bullish Trade ContinuationHello fellow traders, If it fits your trading strategy and set up rules, JAGX currently offers great risk-to-reward potential to the upside. Although the larger context is bullish, the weekly timeframe recently completed its expansion and began its corrective phase while maintaining its recently established value. On the lower timeframes we can see a steady correction which don't show any signs of downward conviction on a higher than intra-day timeframe. In the event that the higher timeframes continue to their correction, there are great odds for a stronger dip below current value before the probable move upwards. Let me know if you like the idea with a thumbs up. Enjoy your day.
NASDAQ:JAGXLong
by Elexzo
JAGX Would you buy something that was 10000x more expensive? Jaguar Health, Inc. is a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. July 20, 2020 : Jaguar Health, Inc. announced today that it has submitted to the U.S. Food and Drug Administration's Center for Veterinary Medicine the second-to-last required technical section to support approval of Jaguar's oral plant-based drug candidate Canalevia™ (crofelemer delayed-release tablets) to treat chemotherapy-induced diarrhea in dogs, although this filing was originally scheduled for submission by the end of August 2020. More than 230,000 dogs in the U.S. receive chemotherapy treatment for various cancers each year, and roughly one in four (more than 50,000 dogs) will experience diarrhea as a side effect of treatment. OASIS CAPITAL LLC REPORTS 9.99% PASSIVE STAKE IN JAGUAR HEALTH AS OF JULY 7- SEC FILING Net Income $-38,540,000 Market Cap $42.15 million Annual Sales $5.78 million Debt-to-Equity Ratio 0.08 JAGX is a risky bet that can double your money in seconds. Not trading advice. If you are interested to test some amazing buy and sell indicators, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:JAGXLong
by TopgOptions
5